At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 102 enrolled
Drug / intervention
Iron Isomaltoside 1000 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
In Brief
A Phase 3 clinical trial evaluating Iron Isomaltoside 1000 and Placebo: NaCl 0,9% for Heart Transplant Recipients. Completed, enrolled 102 participants across 1 site.
Detailed Summary
Iron deficiency is prevalent in heart transplant recipients, and may be associated with reduced functional capacity. The IronIC trial is designed to assess the effect of intravenous iron isomaltoside on exercise capacity, muscle strength, cognition and quality of life in iron-deficient heart transplant recipients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Transplant Recipients
CountriesNorway
CollaboratorsPharmacosmos A/S
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartApr 2018
First PostedSep 2018
Primary CompletionFeb 2020
TodayJul 2026
First PostedSep 7, 2018
Enrollment StartApr 25, 2018
Primary CompletionFeb 27, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.8 years ago
Interventions
Iron Isomaltoside 1000drug
Intravenous infusion
Placebo: NaCl 0,9%other
Intravenous infusion